Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lisa Levin

27 Stocks Moving in Thursday's Pre-Market Session

Gainers

  • Heart Test Laboratories, Inc. (NASDAQ:HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.
  • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) rose 27.1% to $0.1790 in pre-market trading after declining around 15% on Wednesday. Electric Last Mile Solutions recently announced plans to file for Chapter 7 bankruptcy.
  • Senti Biosciences, Inc. (NASDAQ:SNTI) rose 19% to $2.44 in pre-market trading after declining around 15% on Wednesday.
  • Redbox Entertainment Inc. (NASDAQ:RDBX) rose 18.6% to $13.00 in pre-market trading after gaining around 9% on Wednesday.
  • Alset EHome International Inc. (NASDAQ:AEI) rose 17.1% to $0.3560 in pre-market trading.
  • GreenPower Motor Company Inc. (NASDAQ:GP) shares rose 14.5% to $3.88 in pre-market trading.
  • Applied Therapeutics, Inc. (NASDAQ:APLT) rose 12.7% to $1.24 in pre-market trading.
  • Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 12.2% to $0.68 in pre-market trading after gaining over 4% on Wednesday.
  • Embark Technology, Inc. (NASDAQ:EMBK) rose 11.5% to $0.7267 in pre-market trading.
  • Secoo Holding Limited (NASDAQ:SECO) shares rose 11.1% to $0.25 in pre-market trading after declining 5% on Wednesday.
  • Gamida Cell Ltd. (NASDAQ:GMDA) rose 9.3% to $2.11 in pre-market trading after gaining around 5% on Wednesday.
  • BARK, Inc. (NYSE:BARK) rose 8.9% to $1.59 in pre-market trading.
  • Sidus Space, Inc. (NASDAQ:SIDU) rose 8.5% to $5.08 in pre-market trading. Sidus Space shares jumped 225% on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
  • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) rose 8.1% to $3.73 in pre-market trading. Rhythm Pharmaceuticals recently presented initial data from long-term extension trial evaluating setmelanotide in rare genetic diseases of obesity at ENDO 2022.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.